FDA Approves Updated COVID-19 Vaccines for 2026-2027
Updated formulas from Pfizer, Moderna, and Novavax target the circulating XFG variant for older adults and high-risk populations.
Tag: Novavax
All
Latest
FDA Approves Updated COVID-19 Vaccines for 2026-2027
Updated formulas from Pfizer, Moderna, and Novavax target the circulating XFG variant for older adults and high-risk populations.
Read More
Novavax Begins Phase 3 Trial for COVID-19-Flu Combo Vaccine
Novavax has begun a phase 3 trial evaluating its COVID-19-influenza combination vaccine in adults aged 65 and older.
Read More
FDA Lifts Clinical Hold on Novavax’s COVID-Flu Vaccine Trial
The FDA removed the clinical hold on Novavax’s COVID-19-influenza combination vaccine, allowing the company to proceed with its planned phase 3 trial.
Read MoreFDA Places Hold on Novavax’s COVID-Flu Vaccine IND After Adverse Event
The FDA has placed a hold on Novavax’s Investigational New Drug application for its COVID-19-influenza combination and stand-alone influenza vaccines following a report of an adverse event in a participant from the completed combination trial.
Read More
FDA Authorizes Updated Novavax COVID-19 Vaccine
The FDA has granted emergency use authorization for an updated Novavax COVID-19 vaccine targeting current variants.
Read More
FDA Authorizes Updated Novavax COVID-19 Vaccine
The FDA amended the emergency use authorization of the Novavax COVID-19 vaccine, adjuvanted to include the 2023-2024 formula.
Read More
EU Authorizes Novavax COVID-19 Vaccine
The vaccine is now fully authorized for use as a primary series in individuals aged 12 and older and as a booster dose in adults aged 18 and older for the prevention of COVID-19.
Read More
Vaccines: Europe OK’s Novavax’s COVID-19 Vaccine Booster
The European Commission expanded the approval of Novavax’s COVID-19 vaccine as a booster for adults aged 18 and older.
Read More
Vaccines: Omicron-specific Covid Booster Shots are Arriving Soon
Updated Covid booster shots targeting omicron’s BA.5 subvariant should be here within in the next three weeks.
Read More
Coronaviruses Can Survive on Frozen Meat
The Biden administration announced on Monday that it would buy 3.2 million doses of a Covid-19 vaccine from the Maryland pharmaceutical company Novavax that is expected to soon receive authorization in the United States.
Read More
FDA Authorizes Novavax COVID Vaccine
The FDA issued an emergency use authorization for the Novavax COVID vaccine (adjuvanted) for Americans 18 years of age and older.
Read More
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Although the U.S. commitment to developing Novavax’s COVID vaccine ballooned to $1.8 billion, hardly any Novavax shots have found arms due to manufacturing issues.
Read More
Novavax’s COVID-19 Booster to be Evaluated in NIH Study
Novavax said Friday that its COVID-19 vaccine is being tested in a clinical trial sponsored by the National Institutes of Health.
Read More
Canada Authorizes Novavax COVID-19 Vaccine for Adults
Health Canada has granted authorization for Novavax Inc’s COVID-19 vaccine “Nuvaxovid” for adults age 18 and older.
Read More
Positive Results for Novavax Vaccine in Children
Novavax Inc’s COVID-19 vaccine demonstrated 80% efficacy overall in a study of over 2,000 pediatric patients when the Delta variant was the predominant circulating strain in the US.
Read More
Novavax Vaccine Authorized in Great Britain, New Zealand
Novavax Inc has received authorizations for its COVID-19 vaccine NVX-CoV2373 (brand name Nuvaxovid) in Great Britain and in New Zealand, the company reports.
Read More
Novavax Vaccine Submitted for FDA Emergency Use Authorization
Novavax Inc has submitted a request to the US FDA for Emergency Use Authorization for its COVID-19 vaccine NVX-CoV2373 for patients 18 and older.
Read More
Novavax Vaccine to Ship to EU in Q1
Novavax is expected to start delivering COVID-19 vaccine doses to the European Union in the first quarter 2022, according to a report from Reuters.
Read More
Study: Novavax Vaccine Safe and Effective
An investigational COVID-19 vaccine made by Novavax was found to be 90% effective at preventing COVID-19 illness.
Read More
Positive Data for Coadministered Flu and COVID Vaccines
Positive results from the first co-administration study of a SARS-CoV-2 vaccine candidate and an approved influenza vaccine have been published in The Lancet Respiratory Medicine.
Read More
Novavax Pursuing UK Authorization for COVID-19 Vaccine
Novavax has completed its rolling regulatory submission for authorization of its NVX-CoV2373 COVID-19 vaccine candidate in the United Kingdom.
Read More
Novavax COVID-19 Vaccine 90% Effective Overall in Ph3 Trial
Novavax Inc’s COVID-19 vaccine NVX-CoV2373 demonstrated 90.4% overall efficacy against SARS-CoV-2 infection, and 100% protection against moderate and severe disease, according to a Phase 3 PREVENT-19 clinical trial.
Read More
Novavax COVID-19 Vaccine Candidate 89.5% Effective in UK PH3 Trial
Novavax Inc’s COVID-19 vaccine candidate had a vaccine efficacy of 89.3% in a Phase 3 UK clinical trial, but appeared less effective (60%) against a South Africa variant.
Read More
Novavax COVID-19 Vaccine Enters Ph3 Trials
The Novavax vaccine is the fifth COVID-19 vaccine candidate to begin clinical trials, after Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson & Johnson.
Read More